CAS: 157599-02-5; 2,2',2'',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetrayl)Tetraacetamide

相似化合物

114873-37-9 865470-67-3 60239-18-1

上下游产品

CAS号294-90-6 轮环藤宁 | CAS号79-07-2 氯乙酰胺 | CAS号683-57-8 2-溴乙酰胺

📜轮环藤宁,氯乙酰胺置于三乙胺体系中,用 乙醇 用作溶剂,化学反应生成1,4,7,10-四(氨基羰甲基)-1,4,7,10-四氮杂环十二烷
参考文献:Stability Enhancement Of Heavy-Metal-macrocycle Complexes Via Pendant Amide Coordination
标题:Stability Enhancement Of Heavy-Metal-macrocycle Complexes Via Pendant Amide Coordination
摘要:悬臂大环配体 1,4,7,10-四(氨基甲酰基甲基)-1,4,7,10-四氮杂环十二烷 L 的形成及其随后生成的镉(II)络合物表明,与相关大环镉(II)络合物相比,该络合物具有非常显著的稳定性,而相关大环镉(II)络合物要么完全缺乏悬臂供体,要么在大环上附有其他类型的中性氧供体,与 L 与较轻金属离子的络合物相比也是如此.
Doi:10.1039/c39940001007

专利信息

专利号:WO-2025088147-A1
优先权日:2023-10-27
标题 :Theranostic psma-targeting ligands for the diagnosis and treatment of psma-expressing cancers and their solid phase synthesis
发明人：Schäfer Martin; BAUDER-WUEST ULRIKE; ROSCHER MAREIKE; REMDE YVONNE; BENEÅ OVÃ?-SCHÄFER MARTINA; BARINKA CYRIL; KUTILOVÃ? ZSÓFIA; MOTLOVÃ? LUCIA
权利人:DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
摘要:The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and radiopharmaceuticals for the treatment of various disease states of PSMA-expressing cancers, especially prostate cancer, and metastases thereof. Further the present invention provides synthetic procedures for the synthesis of such PSMA-targeting ligands.

专利号:US-10927132-B2
优先权日:2015-02-27
标 题 :Transmetalation methods for the synthesis of PET and SPECT imaging agents
发明人：SCHMITTHENNER HANS F; SWEENEY-JONES ANNE M; WILLIAMS SCOTT
权利人:SCHMITTHENNER HANS F; SWEENEY JONES ANNE M; WILLIAMS SCOTT; ROCHESTER INSTITUTE TECH
摘要:A process for the preparation of a radionuclide imaging agent includes providing an imaging agent including a chelated place-holder metal; loading the imaging agent onto an acid stable stationary phase; replacing the chelated place-holder metal of the imaging agent loaded on the stationary phase with a replacement radioactive metal under mild reaction conditions; and eluting the imaging agent including the chelated replacement radioactive metal from the stationary phase to provide a radionuclide imaging agent suitable for positron emission tomography (PET) or single-photon emission computed tomography (SPECT). The imaging agent can include a targeting agent that is directly conjugated to the imaging agent or by means of a linker. The process may also apply to other metals that are non-radioactive but used as diluent metals or other metals that are strongly bound to DOTA.

专利号:US-2016251378-A1
优先权日:2015-02-27
标题 :Transmetalation Methods for the Synthesis of PET and SPECT Imaging Agents

专利号:EP-3283128-A4
优先权日:2015-02-27
标 题:TRANSMETALIZATION PROCEDURE FOR SYNTHESIS OF PET AND SPECT CONTRASTANTS

专利号:US-2024207458-A1
优先权日:2021-04-26
标 题:Targeted alpha particle therapy for somatostatin receptor 2 positive neuroendocrine tumors and metastases
发明人：MORSE DAVID; JI HAITAO; WADAS THADDEUS; PANDYA DARPAN
权利人:H LEE MOFFITT CANCER CT & RES
摘要:Disclosed are TATE derivatives having a linker between the TATE moiety and a macrocyclic radionuclide chelating moiety. Methods of synthesis and use are also disclosed. The compounds preferably exhibit a ratio of kidney: liver uptake by a subject within 24 hours of 5 or less, 3 or less, 1 or less, 0.5 or less, preferably from 2:1 to 1:2.

专利号:US-10610608-B2
优先权日:2013-08-01
标题 :Modular imaging agents containing amino acids and peptides
发明人：SCHMITTHENNER HANS F; BEACH STEPHANIE; BARRETT TAYLOR; WEIDMAN CHELSEA
权利人:SCHMITTHENNER HANS F; BEACH STEPHANIE; BARRETT TAYLOR; WEIDMAN CHELSEA; ROCHESTER INSTITUTE TECH
摘要:Targeted molecular imaging agents (TMIAs) are derived from coupling together pre-formed amino acids with imaging agents attached to their side chains. These peptide-based imaging agents may synthesized from a single or multiple preformed amino acids containing multi-modal, multi-chelated metal, multi-dye imaging agents, or combinations of these, on the side chains of resultant peptides. These imaging amino acids or peptides may be conjugated directly, or activated, or attached to linkers to which targeting groups, such as peptides, proteins, antibodies, aptamers, or small molecule inhibitors, may be conjugated in the final steps of the synthesis to form a wide variety of TMIAs.